Rain oncology stock.

WHY: NEW YORK, NY - (NewMediaWire) - September 01, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and May 19, 2023, both dates inclusive (the “Class Period”), of the important September 12, 2023 lead plaintiff deadline. SO WHAT: If …Rain Oncology. stock was originally listed at a price of $15.80 in Apr 23, 2021. If you had invested in Rain Oncology stock at $15.80, your return over the last 2 years would have been -93.23%, for an annualized return of -73.98% (not including any dividends or dividend reinvestments).View the latest Rain Oncology Inc. (RAIN) stock price, news, historical charts, analyst ratings and financial information from WSJ.At Olema Oncology, we leverage our deep understanding of endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance with the goal of transforming the standard of care for women living with cancer by focusing on developing more convenient and effective therapies. Join us as we aim to design therapies for improving lives.

‍ Rain Oncology was founded in 2017 as a precision oncology company leveraging a deep scientific knowledge of drug mechanism and designing clinical trials with the most appropriate patient population most likely to benefit from treatment. Rain is focused on a few critical objectives: (1) strive to greatly enhance probabilities of therapeutic ...Rain Oncology Inc Stock Price History. Rain Oncology Inc’s price is currently up 19.56% so far this month. During the month of January, Rain Oncology Inc’s stock price has reached a high of $14.48 and a low of $7.60. For the year, Rain Oncology Inc has hit prices as high as $14.48 and as low as $2.15. Year to date, Rain Oncology Inc’s ...

Cardiff Oncology stock price target cut to $14 from $25 at Maxim Group. Jan. 24, 2022 at 7:47 a.m. ET by Tomi Kilgore. Cardiff Oncology stock price target raised to $25 from $20 at Maxim Group.Rain Oncology. stock last closed at $1.11, up 5.71% from the previous day, and has decreased 86.09% in one year. It has underperformed other stocks in the Biotechnology industry by 0.59 percentage points. Rain Oncology stock is currently +35.37% from its 52-week low of $0.82, and -92.33% from its 52-week high of $14.48.At …Web

Richard S. Pzena’s Pzena Investment Management is the biggest stakeholder of the company, with 3.86 million shares worth $277.7 million. Like Moderna, Inc. (NASDAQ:MRNA), BeiGene, Ltd. (NASDAQ ...Rain Oncology Inc ( RAIN) is down -3.97%% today. RAIN has an Overall Score of 52. Find out what this means to you and get the rest of the rankings on RAIN! See Full RAIN Report. RAIN stock closed at $1.26 and is down -$0.05 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only ...Exhibit 10.15 FIRST AMENDMENT TO. RAIN THERAPEUTICS INC. 2021. EMPLOYEE STOCK PURCHASE PLAN. WHEREAS, Rain Oncology Inc. (f/k/a Rain Therapeutics Inc.), a Delaware corporation (the “Company”) maintains the Rain Therapeutics Inc. 2021 Employee Stock Purchase Plan (the “Plan”); . WHEREAS, …Rain Oncology Inc 52 week high is $14.48 as of November 24, 2023. What is the 52-week low for Rain Oncology Inc? 52 week low is the lowest price of a stock in the past 52 weeks, or one year.Mar 9, 2023 · Non-cash stock-based compensation expense included in G&A expenses were approximately $0.3 million and $1.1 million for the three months and year ended December 31, 2022, respectively, as compared ...

1 Aug 2023 ... Stocks; ›; ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities ...

Y-mAbs Therapeutics, Inc. (Y-mAbs), is a state-of-the-art, late-stage clinical, global biopharmaceutical company that is focused on the research and development of innovative antibody-based products under investigation using a range of cutting-edge technologies, licensed from one of the largest and most prestigious cancer-care …

Rain Oncology Inc. Watch list NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:58 p.m. EST Delayed quote $ 1.1100 0.00 0.00% After Hours Volume: 1.31K …Most recently, on Monday, November 21st, Franklin M. Berger bought 45,000 shares of Rain Oncology stock. The stock was acquired at an average cost of $7.80 per share, with a total value of $351,000.00. Following the completion of the transaction, the director now directly owns 928,207 shares of the company's stock, valued at …WebRain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company’s lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain ...Company Overview. Rain Oncology is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than ...Web1.0900. +0.0200. +1.87%. Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 ...Web12 brokers have issued 12-month price objectives for Rain Oncology's stock. Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate …Nanopore design. The concept of nanopore sequencing emerged in the 1980s and was realized through a series of technical advances in both the nanopore and the associated motor protein 1,4,5,6,7,8 ...

As of November 3, 2023, Rain had approximately 36.4 million shares of common stock outstanding. About Rain Oncology Inc. Rain Oncology Inc. is a precision oncology company developing therapies ...WebMar 13, 2023 · 1.0900. +0.0200. +1.87%. Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 ... This two-day volume growth resulted in a record-breaking increase of 285%, as compared to the 65-Day Volume Moving Average. RAIN's total volume now sits at 561.8K. In addition to the volume jump, the stock experienced a slight price change of 7.07%, setting the new price at $1.06. This volume move could indicate a change in trend, and may be a buy …Predictive Oncology Inc. (NASDAQ:POAI) posted its earnings results on Wednesday, August, 11th. The medical instruments supplier reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.60) by $0.60. The medical instruments supplier earned $0.35 million during the quarter, compared to …Nov 4, 2022 · NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ... Rain Oncology Inc. (RAIN) Stock Price | Stock Quote Nasdaq - MarketScreener RAIN ONCOLOGY INC. Rain Oncology Inc. Stock price Equities …NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock.

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...

View Rain Oncology Inc RAIN investment & stock information. Get the latest Rain Oncology Inc RAIN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Jan 20, 2023 · Stock and Other Ownership Interests: Rain Oncology Consulting or Advisory Role: GreenPeptide, AstraZeneca, Roche/Genentech, Rain Oncology, Blueprint Medicines, Guardant Health Patents, Royalties, Other Intellectual Property: Licensing fees for patent from Rain Oncology, Licensing fees from Takeda for Biologic Materials, Licensing fees from ... 23 May 2023 ... In the last 3 months, 8 analysts have offered 12-month price targets for Rain Oncology. The company has an average price target of $10.91 with a ...16 Oct 2023 ... Rain's shares had previously been riding far higher than that, ranging between $7 and $10 apiece for the first four months of the year, until ...Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting …WebDescription. Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology.Web

11 Aug 2023 ... Analyst Jason Zemansky thinks Kura Oncology could be a winner in blood cancer treatment, believing the stock could nearly triple in value.

Nov 4, 2022 · NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...

Development of the RAINFALL study rationale and protocol included review of National Comprehensive Cancer Network, European Society for Medical Oncology, and Japanese Gastric Cancer Association treatment guidelines, PubMed, and abstracts of major oncology congresses from 2009 to 2014, with MeSH and full-text search terms for clinical trials of …What is the target price for Rain Oncology (RAIN) stock? The latest price target for Rain Oncology ( NASDAQ: RAIN) was reported by Citigroup on Monday, September 18, 2023. The analyst firm set a ... JaysonPhotography. Rain Oncology (NASDAQ:RAIN) continued to fall in the pre-market Tuesday after multiple analysts downgraded the company on its decision to halt studies for its lead asset ...1.05. +0.03. +2.94%. Get Rain Oncology Inc (RAIN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Rain Oncology is a late-stage oncology company specializing in precision oncology by targeting oncogenic drivers. Click here to see why the stock is a speculative buy.Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.Rain Oncology Quote Info ; Resistance 2, 1.17 ; Trades, 720 ; 52 Week Range, 0.82 - 14.48 ; VWAP, $ 1.08 ; Dollar Volume, $ 162,169.7 Sept 2023 ... SHAREHOLDER ALERT: Levi & Korsinsky Notifies Rain Oncology Inc.(RAIN) Investors of a Class Action Lawsuit and Upcoming Deadline. Levi & ...

Rain Oncology Inc (RAIN) stock is down -87.44% while the S&P 500 has risen 0.1% as of 11:09 AM on Monday, May 22. RAIN is down -$8.68 from the previous closing price of $9.93 on volume of 16,197,454 shares. Over the past year the S&P 500 is higher by 5.60% while RAIN is down -51.92%. RAIN lost -$2.61 per share in the over the last 12 months.Jun 21, 2023 · NEW YORK, June 21, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rain Oncology Inc.:. On or around April 22, 2021, Rain conducted its initial public offering ("IPO"), selling more than 7.35 million shares priced at $17.00. NEWARK, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology... – Quarter-end cash position of $123.2 million provides ample cash runway into first half of 2024 – – Phase 3 MANTRA topline data expected earlier than... Instagram:https://instagram. how to trade futures on fidelityapp bank accountsjepi distributionis walmart stock a good investment 22 May 2023 ... Milademetan in Liposarcoma: © Dr_Microbe - stock.adobe.com ... Rain oncology announces topline results from phase 3 MANTRA trial of ... cryptocurrency portfolio trackerford down 1.05. +0.03. +2.94%. Get Rain Oncology Inc (RAIN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.RAIN News Today | Why did Rain Oncology stock go up today? S&P 500 4,559.34. DOW 35,390.15. QQQ 389.51. 12 crew members are missing, 1 dead after a cargo ship sinks off a Greek island in stormy seas. [Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad) Turned down for a loan, business owners look to family and even ... short tesla stock Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress ... Non-cash stock-based compensation expenses included in R&D expenses were approximately $1.1 million in the three months ended March 31, 2023, as compared to $0.9 million in the same period in 2022. General and administrative (G&A) …WebMar 9, 2023 · NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with its product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reports financial results for the fourth ...